Switzerland And Greifswald

LUGANO, Switzerland and GREIFSWALD, Germany, September 27, 2011 - License Agreement for Germany on New Therapy in Development for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) Helsinn Healthcare SA, Switzerland and Riemser Arzneimittel AG, German licensee of Helsinn's second generation 5-HT3 receptor antagonist palonosetron, announce today the signing of a licensing agreement granting Riemser the commercialization rights for a next-generation treatment in development by Helsinn for the prevention of chemotherapy-induced nausea and vomiting (CINV) in Germany.